Myricetin


Literature identifierStudy typeTest dosageEffective dosageEndocrine-mediated endpointsSystems-level perturbations
PMID:24487097IVR100 mg/kg/day 100 mg/kg/dayChanges in epididymal morphologyReproductive endocrine-mediated perturbations
IVR100 mg/kg/day 100 mg/kg/dayAlterations in vaginal openingReproductive endocrine-mediated perturbations
IVR100 mg/kg/day 100 mg/kg/dayAffects uterine morphologyReproductive endocrine-mediated perturbations
IVR100 mg/kg/day 100 mg/kg/dayIncreased uterine weightsReproductive endocrine-mediated perturbations
IVR10 mg/kg/day 10 mg/kg/dayAffects uterine morphologyReproductive endocrine-mediated perturbations
IVR10 mg/kg/day 10 mg/kg/dayChanges in epididymal morphologyReproductive endocrine-mediated perturbations
IVR1 mg/kg/day 1 mg/kg/dayChanges in epididymal morphologyReproductive endocrine-mediated perturbations
IVR1 mg/kg/day 1 mg/kg/dayAffects uterine morphologyReproductive endocrine-mediated perturbations

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.